Cannabis Withdrawal Syndrome
A real, well-documented syndrome that shows up in heavy users when they quit, usually peaks in the first week, and resolves within a month.
For decades people insisted cannabis wasn't addictive and had no withdrawal. That was wrong. Cannabis withdrawal syndrome is real, it's in the DSM-5, and it happens to a meaningful minority of regular users when they stop. The good news: it's rarely dangerous, usually peaks within a week, and resolves in 2-4 weeks. The bad news: there's no FDA-approved medication for it, and most 'treatments' you'll read about online range from modestly helpful to complete folklore.
Plain-language summary
If you use cannabis heavily and daily and then stop, there's a real chance you'll feel bad for a week or two. This isn't in your head and it isn't weakness. The most common symptoms are irritability, anxiety, sleep problems (including vivid dreams), decreased appetite, restlessness, and a depressed mood. Physical symptoms like sweating, chills, headache, and stomach pain also happen but are usually milder [1][2].
Roughly half of people who try to quit after heavy regular use experience clinically meaningful withdrawal [3]. Symptoms typically start within 24-72 hours, peak in the first week, and mostly resolve within two weeks — though sleep disruption can linger for a month or more [1][4].
Unlike alcohol or benzodiazepine withdrawal, cannabis withdrawal is not medically dangerous. Nobody has seizures. Nobody dies from it. But it is uncomfortable enough that it drives a lot of relapse, which is the main clinical reason it matters [2][5].
This article is not medical advice. If you are trying to quit and struggling, talk to a clinician — especially if you have co-occurring depression, anxiety, or another substance use disorder.
What probably works
Cognitive behavioral therapy (CBT), motivational enhancement therapy (MET), and contingency management — usually in combination — are the best-supported interventions for cannabis use disorder and, indirectly, for getting through withdrawal without relapse Strong evidence. A large meta-analysis found combined CBT+MET+contingency management produced the biggest reductions in frequency of use and increased abstinence rates [6].
Time and expectation-setting. Knowing that symptoms peak around day 2-6 and fade by week 2 is itself protective. People who understand the timeline are less likely to relapse to 'fix' what they assume is a permanent problem Strong evidence[1].
Sleep hygiene basics — consistent wake time, morning light, limiting late caffeine, avoiding screens in bed — help with the insomnia that's often the worst and longest-lasting symptom [evidence:weak, extrapolated from general insomnia literature]. No cannabis-specific RCTs, but low-risk and cheap.
Agonist substitution with dronabinol or nabiximols (oral THC or a THC:CBD spray) reduces withdrawal severity in inpatient and outpatient trials [evidence:strong for symptom relief]. However, they do not reliably increase long-term abstinence [7][8]. Think of them like nicotine replacement: useful for the acute discomfort, not a cure.
What might work
Gabapentin showed reduced withdrawal symptoms and improved abstinence in a small (n=50) placebo-controlled trial at 1200 mg/day [9]. Promising but not replicated at scale Weak / limited.
N-acetylcysteine (NAC) showed benefit in adolescents in one trial [10] but failed to replicate in adults in a larger multi-site trial [11]. Currently Disputed, leaning negative for adults.
Exercise. Small studies suggest aerobic exercise reduces craving and use in cannabis-dependent adults [12]. Plausible mechanism, low risk, but small evidence base Weak / limited.
CBD. A 2020 phase 2a trial (Freeman et al.) found 400 mg and 800 mg daily CBD reduced cannabis use in people with CUD [13]. Interesting signal, needs replication Weak / limited.
Cannabinoid FAAH inhibitors (e.g., PF-04457845) showed reduced withdrawal symptoms in one trial [14] but development has been slow and safety concerns from an unrelated FAAH drug (BIA 10-2474) chilled the field Weak / limited.
What doesn't work, or where evidence is weak
Bupropion. A controlled trial found it did not reduce withdrawal and may have worsened irritability and sleep [15] [evidence:strong-negative].
Quetiapine. Reduced some symptoms but increased cannabis craving and use in an outpatient trial — a bad tradeoff [16] [evidence:strong-negative].
Naltrexone. Mixed and generally disappointing results for cannabis use disorder Weak / limited.
'Tapering' by switching to CBD-only flower, kratom, or kava. No controlled evidence any of these help with cannabis withdrawal specifically No data. Popular on forums; not studied.
Detox teas, 'THC flushes,' and cleanse products. These target drug-test detection, not withdrawal, and don't reliably do that either No data.
Going back to smaller amounts of cannabis to 'taper.' No RCT evidence this works better than abrupt cessation, and it prolongs exposure to the reinforcer No data. Note this is different from clinician-supervised agonist substitution with dronabinol/nabiximols, which uses standardized dosing.
What we don't know
- Why some heavy users get severe withdrawal and others get almost none. Genetics, baseline anxiety, and CB1 receptor downregulation all matter, but no clinically useful predictor exists.
- Whether high-potency concentrates (dabs, vapes at 70-90% THC) produce a distinct or more severe withdrawal syndrome than flower. Clinically it looks worse, but rigorous comparative data are thin Weak / limited.
- Long-term trajectory of protracted symptoms (sleep, mood) beyond 30 days. Most trials end at 4 weeks.
- Whether CBD, at what dose, actually helps — or is just novelty.
- Optimal treatment for adolescents, who metabolize and respond differently.
- Whether medical cannabis patients using cannabis for pain, PTSD, or sleep experience withdrawal differently from recreational users when tapering.
Comparison with other substance withdrawal syndromes
| Substance | Life-threatening? | Peak | Duration | FDA-approved meds | |---|---|---|---|---| | Alcohol | Yes (seizures, DTs) | 24-72 hr | 5-7 days acute | Benzos, phenobarbital | | Benzodiazepines | Yes (seizures) | Variable | Weeks to months | Slow taper | | Opioids | Rarely (dehydration) | 36-72 hr | 5-10 days | Methadone, buprenorphine, lofexidine | | Nicotine | No | 2-3 days | 2-4 weeks | NRT, varenicline, bupropion | | Cannabis | No | 2-6 days | 1-2 weeks (sleep up to 30+ days) | None |
Cannabis withdrawal sits closest to nicotine in severity and risk profile: uncomfortable, drives relapse, but not medically dangerous [1][2]. The clinical gap is that nicotine has three approved pharmacotherapies and cannabis has zero.
Risks and when to seek help
The main risk of cannabis withdrawal isn't withdrawal itself — it's relapse and worsening of underlying mental health conditions.
- Suicidal ideation can emerge or worsen during withdrawal, especially in people with prior depression [17]. This is a reason to seek help, not push through alone.
- Anxiety and panic can spike, and people sometimes reach for alcohol or benzodiazepines to cope — creating a new problem.
- Sleep deprivation from insomnia can impair driving and work performance.
- People using cannabis to self-treat PTSD, chronic pain, or nausea may see those underlying conditions rebound hard.
Seek professional help if: symptoms are severe, you have suicidal thoughts, you have co-occurring substance use, you've tried to quit multiple times and can't, or you're using cannabis to manage a diagnosed condition. SAMHSA's National Helpline (1-800-662-4357, US) is free, confidential, and 24/7.
This article is not medical advice. It is educational information. Talk to a licensed clinician about your specific situation.
Sources
- Peer-reviewed Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Substance Abuse and Rehabilitation. 2017;8:9-37.
- Peer-reviewed Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Current Opinion in Psychiatry. 2006;19(3):233-238.
- Peer-reviewed Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Network Open. 2020;3(4):e202370.
- Peer-reviewed Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. Journal of Abnormal Psychology. 2003;112(3):393-402.
- Peer-reviewed Levin KH, Copersino ML, Heishman SJ, et al. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug and Alcohol Dependence. 2010;111(1-2):120-127.
- Peer-reviewed Gates PJ, Sabioni P, Copeland J, Le Foll B, Gowing L. Psychosocial interventions for cannabis use disorder. Cochrane Database of Systematic Reviews. 2016;(5):CD005336.
- Peer-reviewed Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug and Alcohol Dependence. 2011;116(1-3):142-150.
- Peer-reviewed Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281-291.
- Peer-reviewed Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689-1698.
- Peer-reviewed Gray KM, Carpenter MJ, Baker NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. American Journal of Psychiatry. 2012;169(8):805-812.
- Peer-reviewed Gray KM, Sonne SC, McClure EA, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug and Alcohol Dependence. 2017;177:249-257.
- Peer-reviewed Buchowski MS, Meade NN, Charboneau E, et al. Aerobic exercise training reduces cannabis craving and use in non-treatment seeking cannabis-dependent adults. PLoS ONE. 2011;6(3):e17465.
- Peer-reviewed Freeman TP, Hindocha C, Baio G, et al. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. The Lancet Psychiatry. 2020;7(10):865-874.
- Peer-reviewed D'Souza DC, Cortes-Briones J, Creatura G, et al. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The Lancet Psychiatry. 2019;6(1):35-45.
- Peer-reviewed Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology. 2001;155(2):171-179.
- Peer-reviewed Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addiction Biology. 2013;18(6):993-1002.
- Peer-reviewed Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug and Alcohol Dependence. 2019;195:170-177.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...